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Nonalcoholic fatty liver disease (NAFLD) is a chronic condition characterized by fat
accumulation combined with low‐grade inflammation in the liver. A large body of clin-
ical and experimental data shows that increased flux of free fatty acids from increased
visceral adipose tissue and de novo lipogenesis can lead to NAFLD and insulin resis-
tance. Thus, individuals with obesity, insulin resistance, and dyslipidaemia are at the
greatest risk of developing NAFLD. Conversely, NAFLD is a phenotype of cardiomet-
abolic syndrome. Notably, researchers have discovered a close association between
NAFLD and impaired glucose metabolism and focused on the role of NAFLD in the
development of type 2 diabetes. Moreover, recent studies provide substantial evi-
dence for an association between NAFLD and atherosclerosis and cardiometabolic
disorders. Even if NAFLD can progress into severe liver disorders including nonalco-
holic steatohepatitis (NASH) and cirrhosis, the majority of subjects with NAFLD die
from cardiovascular disease eventually. In this review, we propose a potential patho-
logical link between NAFLD/NASH and cardiometabolic syndrome. The potential fac-
tors that can play a pivotal role in this link, such as inflammation, insulin resistance,
alteration in lipid metabolism, oxidative stress, genetic predisposition, and gut micro-
biota are discussed.
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1.1 | Prevalence of nonalcoholic fatty liver disease
(NAFLD)/nonalcoholic steatohepatitis (NASH)
NAFLD covers a spectrum of diseases ranging from simple steatosis to
NASH, which is distinguished from the former by the presence of pro-
gressive hepatic fibrosis.1,2 The prevalence of NAFLD or NASH in theB, apolipoprotein‐B; AST, aspartat
, free fatty acid; FIAF, fasting‐indu
terminal kinase; LPL, lipoprotein li
or‐κB; PAI‐1, plasminogen activa
in 1; T2D, type 2 diabetes; TLR
amyltranspeptidase
wileyonlinelibrary.com/jgeneral population varies according to the diagnostic criteria and tools
used to stage the condition.3,4 In the United States, liver biopsies per-
formed on potential liver donors revealed that 20% of donors were
ineligible for organ donation because of a high degree of steatosis
(>30%).5 A study in which liver biopsies were performed on 589 con-
secutive potential liver‐transplant donors found an NAFLD prevalence
of 51%.6 A series of autopsies showed a broad range in the prevalence
of NAFLD. The prevalence of NASH in autopsy cases of leane aminotransferase; ChREBP, carbohydrate‐responsive element‐binding protein;
ced adipocyte factor; GSK‐3β, glycogen synthase kinase‐3β; IL‐6, interleukin‐6;
pase; LPS, lipopolysaccharide; NAFLD, nonalcoholic fatty liver disease; NASH,
tor inhibitor‐1; ROS, reactive oxygen species; SCFA, short‐chain fatty acid;
, Toll‐like receptor; TNFα, tumour necrosis factor‐α; VLDL, very low‐density
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600 LIM ET AL.individuals from Canada reported in 1990 was 3%.7 A study in India
found fatty liver in 16% of 1230 adult autopsies.8 Another study on
autopsies of cases arising from sudden death and accidents in Greece
reported a prevalence of 31% and 40% for NAFLD and NASH, respec-
tively.9 Taken together, the global prevalence of NAFLD is estimated
to be 25% to 30% with highest prevalence in the Middle East and
South America and lowest in Africa.4
Recently, noninvasive imaging techniques, such as magnetic reso-
nance imaging (MRI), computed tomography (CT), and ultrasonogra-
phy, have been used to measure fat accumulation in the liver. In the
United States, a study with MRI identified an NAFLD prevalence of
31% among a multiethnic population.10 In Spain, the prevalence of
NAFLD on ultrasonography was 33% in men and 20% in women.11
In a study in Italy that used ultrasonography, the prevalence of NAFLD
was 20% in subjects without suspected liver disease.12 The prevalence
of NAFLD identified via ultrasonography in 35 519 Japanese
increased from 13% to 30% over 12 years.13 Recently, diagnosis of
NAFLD in the community has increased fivefold, particularly in young
adults.14 These data suggest that the prevalence of NAFLD in theTABLE 1 Prevalence of NAFLD in different ethnic groups
Ethnicity Setting
Total
Subjects Definition of NAFLD
USA White from a
population‐based
sample





401 Hepatic triglyceride content
>5.5%
Black from a population‐
based sample
1105 Hepatic triglyceride content
>5.5%
Spanish A multicenter, cross‐
sectional, populational
study







1118 Semiquantitation using incre
liver echotexture compare
with the kidneys
Hungarian A cross‐sectional twin
study
208 Semiquantitation using incre
liver echotexture compare
with the kidneys
Finnish The Helsinki birth cohort
study
1611 Fatty liver index >60
Finnish The cardiovascular risk in
young Finns study
1998 Semiquantitation using incre
liver echotexture compare
with the kidneys
Korean A health examination
programme
161 891 Semiquantitation using incre
liver echotexture compare
with the kidneys
Chinese A health examination
programme
6448 Semiquantitation using incre
liver echotexture compare
with the kidneys
Taiwanese A health examination
programme
6511 Semiquantitation using incre
liver echotexture compare
with the kidneys
Abbreviation: NA, not available.
aMean ± SD or ranges.general population is 20% to 40% with minor variation by age, region,
or ethnicity, and that the incidence of disease is increasing over time
in many countries4,15-22 (Table 1). A recent meta‐analysis involving
35,599 patients with type 2 diabetes (T2D) reported that the pooled
prevalence of NAFLD in these patients was 59.7%.23 Thus, NAFLD
is very common in patients with T2D, with an estimated prevalence
of 60% to 80%.241.2 | The (cardio) metabolic syndrome
Metabolic syndrome indicates a constellation of components, such as
abdominal obesity, high glucose, high blood pressure, high triglyceride
level, and low high‐density lipoprotein (HDL)‐cholesterol level; all of
these increase the risk of metabolic and cardiovascular diseases
(CVDs).25 In recent decades, the term “cardiometabolic syndrome”
has been used in various settings.26,27 The incidence of cardiometa-
bolic syndrome has increased rapidly in many countries in past









































































LIM ET AL. 601diets favouring high‐fat and high‐calorie consumption.28,29 These con-
tributing factors are commonly found in people with NAFLD. Dietary
carbohydrates stimulate de novo lipogenesis in the liver and increase
fat accumulation.30,31 Other evidence supports that excessive energy
intake is apparently associated with fatty liver or elevated liver
enzyme activities, such as alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and γ‐glutamyl transpeptidase (γ‐GT).32 Thus,
large energy intake, particularly fructose or sucrose, induces NAFLD, a
precursor of metabolic disorders as well as its consequence.2 | STUDIES OF THE ASSOCIATION
BETWEEN NAFLD AND CARDIOMETABOLIC
DISORDERS
In a meta‐analysis on 34 043 adults, where NAFLD was defined by
either radiological imaging or histology, patients with NAFLD (36.3%
of the whole population) had a higher risk of CVD events than those
without NAFLD (odds ratio [OR] 1.64; 95% confidence interval [CI],
1.26‐2.13).33 This association with CV events was stronger in patients
with severe NAFLD (OR 2.58; 95% CI, 1.78‐3.75) diagnosed either by
the presence of steatosis on radiological imaging plus either elevated
γ‐GT levels or a high NAFLD fibrosis score or by fibrosis seen in liver
histology. In a retrospective cohort study of 8020 men who
underwent health checkups, the age‐adjusted hazard ratio was 1.23






Rafiq et al37 A NAFLD cohort from the
Cleveland Clinic
Foundation
Liver biopsy 50.2 ± 14
Ekstedt et al38 Consecutive recruitment from
university hospitals
Liver biopsy 51.0 ± 12
Pisto et al39 A population‐based, randomly
recruited cohort
Ultrasound 46 ± 10/
Pais et al40 A retrospective single‐centre
study
Fatty liver index 52 ± 11/









Ultrasound 43.7 ± 16
Olubamwo et al42 Kuopio Ischaemic Heart
Disease Risk Factor
Study cohort
Fatty liver index 51.6 ± 5
Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; OR, odds ratio; C
aMean ± SD or ranges.participants with persistent NAFLD, diagnosed by ultrasonography,
compared with those without NAFLD.34 In the Framingham Heart
Study, fatty liver was associated with a clustering of CV risks after
adjustment for other fat depots, including abdominal visceral fat.35
Another study reported that intrahepatic lipid depot is more closely
linked to CV complications than abdominal visceral fat.36
From this perspective, several studies have investigated the rela-
tionship between NAFLD and the incidence of CV events. Rafiq et al
reported that patients with NAFLD had a significantly higher risk of
developing CV events than did matched controls.37 Of note, a 14‐year
follow‐up study (n = 129) found that patients with biopsy‐proven
NAFLD died from CVDs (15.5%) more than from liver‐related diseases
(2.8%).38 More directly, NAFLD has been found to be a significant pre-
dictor of adverse CV events in middle‐aged populations, independent
of age, gender, body mass index (BMI), smoking, alcohol consumption,
lipid levels, or abnormal blood pressure.39 Thus, much evidence sup-
ports the association of NAFLD with the incidence of CVD, indepen-
dent of traditional risk factors.40-42
In contrast, NAFLD was not associated with an increased risk of
death from all causes, CVD, cancer, or liver disease in the Third US
National Health and Nutrition Examination Survey.43 Another study
with the similar data showed that NAFLD was associated indepen-
dently with an increased risk of CVDs, but not CV mortality over a
14‐year period.44 Table 2 summarizes reports for the association of
NAFLD with CVD. Future longitudinal studies are needed to test any
independent association between NAFLD and CVD.ascular disease (CVD)
Follow‐up (y) Main Findings
.5/39.9 18.5 (median) The cause of death was coronary
artery disease (12.7%), followed
by malignancy (8.1%) and liver‐
related death (6.9%)
.9/67.0 13.7 ± 1.3 15.5% patients with NASH died from
CVD, 5.6% from extrahepatic
malignancy, 2.8% from liver‐related
causes
45.2 17.7 Severe liver fat content predicted the
risk for future CV events after
adjusting for conventional risk factors
(HR = 1.74; CI, 1.16‐2.63).
53 8 ± 4 Fatty liver predicted carotid plaque
occurrence (OR = 1.63; 95% CI,
1.10‐2.41), independent of conventional
risk factors
4)/49 14 (median) Subjects with NAFLD showed adjusted
HRs for deaths from all causes of 0.80
(0.52‐1.22), from CVD of 0.59 (0.29‐1.20),
and from liver disease of 1.17 (0.15‐8.93)
compared with those without
.7/28.4 14.25
(median)
NAFLD was associated independently with
CVD, after adjusting for major risk factors
(OR = 1.23; 95% CI, 1.04‐1.44) but not
with CV mortality
.7/41.3 21.1 ± 7.6 High fatty liver index was significant for
incident CVD (HR = 1.41; 95% CI, 1.10‐1.79)
in the comprehensive adjusted model
I, confidence interval.
602 LIM ET AL.3 | PATHOLOGICAL ROLE OF NAFLD AND
CARDIOMETABOLIC SYNDROME
NAFLD is a burgeoning health problem worldwide and an important
risk factor for both hepatic and cardiometabolic morbidity and mortal-
ity. The hallmark features of NAFLD, such as dyslipidaemia, insulin
resistance, inflammation, and oxidative and endoplasmic reticulum
(ER) stress, are shared with cardiometabolic syndrome. The pathogen-
esis of NAFLD involves a complex interaction among environmental
factors including diet and exercise, obesity, alteration in microbiota,
and predisposing genetic traits.3.1 | Increased inflow of free fatty acids and de novo
hepatic lipogenesis are the main determinants of
NAFLD
NAFLD is characterized by excess accumulation of triglycerides in the
hepatocytes due to both increased inflow of free fatty acids (FFAs)
and de novo hepatic lipogenesis in the face of reduced FFA elimina-
tion via very low‐density lipoprotein (VLDL) assembly and β‐oxidation.
The development of hepatic steatosis is influenced by dietary modifi-
cation.45,46 A recent study in nondiabetic persons with obesity
showed that overfeeding with saturated fat increased intrahepatic tri-
glyceride contents.47 Saturated fat also induced insulin resistance andFIGURE 1 Role of inflammation and oxidative stress in the pathogenes
acids (FFAs) released from adipose tissues are influenced by inflammation
antioxidant systems and produce reactive oxygen species (ROS), thereby i
wileyonlinelibrary.com]endotoxaemia and significantly increased the levels of multiple plasma
ceramides, which induce insulin resistance. These data suggest that
saturated fat has a role in hepatic lipogenesis in nondiabetic subjects.
Dietary fructose also stimulates lipogenesis and fat accumulation
in the liver.30 A large body of evidence suggests that increased hepatic
de novo lipogenesis is also a significant pathway contributing to the
development of NAFLD. In an intervention study with a low‐
carbohydrate and high‐protein diet in subjects with obesity and
NAFLD, significant reduction of liver fat and improvement of cardio-
metabolic risk factors were found.48 This finding was associated with
decrease in hepatic de novo lipogenesis, increase in serum β‐
hydroxybutyrate concentrations, and alteration in microbiota. These
results suggest the role of diet‐microbiota interactions for treatment
of NAFLD.483.2 | Inflammatory processes, linked with
cardiometabolic syndrome, are the main determinant
in progression from NAFLD to NASH
Fat accumulation in the liver stimulates the production of inflamma-
tory cytokines (Figure 1).49 In particular, NASH activates the patho-
genesis of cardiometabolic syndrome through the systemic release of
several inflammatory, prothrombotic, and oxidative stress media-
tors.50,51 Nuclear factor‐κB (NF‐κB) and c‐Jun N‐terminal kinaseis of NAFLD/NASH. Under conditions of insulin resistance, free fatty
. Simultaneously, FFAs taken up in the liver decrease the activity of
nducing oxidative stress [Colour figure can be viewed at
LIM ET AL. 603(JNK) are the main intracellular signalling pathways involved in the
mechanistic link between NAFLD and inflammation. The activation
of the NF‐κB pathway in the liver of patients with NAFLD leads to
steatosis, which in turn enhances the transcription of several genes,
such as those for the intercellular adhesion molecule‐1 (ICAM‐1) and
monocyte chemoattractant protein‐1 (MCP‐1). These molecules are
associated with the development or progression of atherosclerosis.52
In a different context, JNK aggravates insulin resistance via the phos-
phorylation and degradation of insulin receptor substrate‐1 (IRS‐1)
and contributes to the inhibition of the intracellular signalling pathway
downstream of the insulin receptor.53
Elevated liver enzyme activity may reflect inflammation, which
impairs insulin signalling both locally and systemically (Figure 2).54 Fur-
thermore, increased levels of inflammatory cytokines, such as C‐
reactive protein (CRP), were observed in patients with NAFLD.55 In
a Japanese study, elevated ALT concentration was found to be an
independent marker of the activation of systemic inflammation and
increased oxidative stress.56 We also showed that individuals in the
top ALT quartile had the highest levels of hsCRP, which was also an
independent predictor of T2D.57
Recent studies have shown novel roles for inflammatory media-
tors in the link between NAFLD/NASH and inflammation. In the
Multi‐Ethnic Study of Atherosclerosis, which is a longitudinal,
population‐based study of four ethnic groups free of CVD at baseline,
levels of interleukin‐6 (IL‐6) were significantly associated with liver fat
assessed via CT after adjusting for other risk factors for atherosclero-
sis.58 Toll‐like receptors (TLRs), which are well‐characterized immuneFIGURE 2 Contributing factors linking NAFLD/NASH with cardiometabo
at wileyonlinelibrary.com]receptors,59 activate proinflammatory pathways.60 Among TLRs,
TLR2 and TLR4 induce insulin resistance, which is pivotal in the path-
ogenesis of NAFLD, obesity, and metabolic syndrome.61 TLR4 is acti-
vated by fatty acids and endotoxaemia, resulting in the activation of
NF‐κB and increased release of inflammatory cytokines, such as IL‐6,
IL‐1β, TNFα, and MCP‐1, which play a critical role in the pathophysi-
ology of cardiometabolic syndrome.623.3 | Lipotoxicity is involved in development of
NAFLD
Lipotoxicity‐related mechanism of NAFLD is linked to the “double‐hit”
theory. In the “first hit,” the hepatic concentrations of diacylglycerols
(DAGs) lead to increase in saturated fat content in liver. Activities of
mitochondrial respiratory chain complexes are decreased in liver tissue
of patients with NASH. Furthermore, lipoapoptosis in hepatocytes is a
critical feature of NASH. In a “second hit,” reduced glutathione levels
caused by oxidative stress lead to overactivation of c‐JNK/c‐Jun sig-
nalling that induces cell death in NASH.63 The ER has oxidation
machinery and ER oxidoreductin‐1 (Ero1) is an essential component
of this.64 Activation of oxidative stress is caused by the abnormal
cycling of Ero1 at the mitochondrial inner membrane.65 Insulin resis-
tance along with a deficiency in IRS‐2‐associated phosphatidylinositol
3‐kinase (PI3K) activity directs FFA flux to pathways that serve to
increase metabolites, such as DAG and ceramides.66 Thus, metabolic
oxidative stress and inflammation induce NASH progression.lic syndrome. ER, endoplasmic reticulum [Colour figure can be viewed
604 LIM ET AL.3.4 | Role of insulin resistance in the development of
NAFLD and cardiometabolic syndrome
Hepatic insulin resistance is a key pathophysiological mechanism of
NAFLD (Figure 1). Recently, liver enzyme activities, which are associ-
ated with insulin resistance, have attracted much attention, as hepatic
dysfunction resulting from intrahepatic lipid deposition contributes to
the development of T2D. Levels of ALT, AST, and γ‐GT are known
indicators of hepatocellular health, and abnormal hepatocellular func-
tion is associated with the onset of T2D. Many prospective studies
have shown that elevated liver enzymes, including ALT, AST, and γ‐
GT, are predictors of the development of insulin resistance, metabolic
syndrome, and T2D in Western populations.67,68 Similarly, serum γ‐GT
level is an important predictor of the development of metabolic syn-
drome and T2D in middle‐aged Japanese men.69 In a prospective
community‐based study conducted in Korea, we found that increased
activity of ALT was associated with a twofold increase in the risk of
T2D, independent of conventional risk factors.57
In a study of NAFLD patients without obesity and control individ-
uals closely matched for age and body composition, the pattern of
metabolic defects observed in NAFLD patients was consistent with
whole body insulin resistance involving the liver, adipose tissue, and
skeletal muscle.70 Even as low as 1.5% triglyceride accumulation in
the liver leads to hepatic insulin resistance, assessed by
hyperinsulinaemic‐euglycaemic clamping.71 In line with this, insulin‐
stimulated glucose disposal assessed by insulin clamping was lower
in patients with NAFLD and T2D than in control subjects.72 Com-
pared with individuals with simple fatty liver, those with NASH had
higher levels of sphingolipids, which are associated with oxidative
stress, inflammation, and insulin resistance assessed by insulin
clamping.73
In addition, it has been reported that elevated hepatic DAG levels
are associated with insulin resistance. Specifically, increased DAG
levels lead to the activation of protein kinase Cε (PKCε), which impairs
insulin‐stimulated tyrosine phosphorylation of IRS‐1 and IRS‐2 and
obstructs activation of PI3K downstream of insulin signalling.74,75
These results suggest that increased hepatic DAG levels play a pivotal
role in the development of NAFLD through deterioration in insulin sig-
nalling.75,76 Other studies have suggested that an increase in hepatic
ceramide content is the major mediator of lipid‐induced hepatic insulin
resistance in the context of NAFLD.77,78 However, the mechanisms by
which ceramides cause hepatic insulin resistance have not been clearly
determined. Thus, fatty acid accumulation in the liver induces insulin
resistance, which contributes to increases in endogenous glucose pro-
duction.79 This acts as a stimulus for further increased whole‐body
insulin resistance, leading to accelerated atherosclerosis.80 Taken
together, as NAFLD is associated with insulin resistance but also
enables the production of a plethora of cardiometabolic risk factors,
the relationship between NAFLD and cardiometabolic risks seems to
be bidirectional and the cause/consequence relationship is difficult
to separate.81
Peripheral insulin resistance contributes to the development of
NAFLD/NASH by aggravating glucose and lipid metabolism
(Figure 2). In healthy people, increased DAG by lipid infusions in skel-
etal muscle was linked with insulin resistance through protein kinaseC‐θ activation.82 Conversely, weight loss with diet or bariatric surgery
effectively treats NAFLD.83
In a different context, sarcopenia, loss of muscle mass, is associated
with NAFLD and diabetes.84,85 People with sarcopenia had a twofold to
threefold increased risk of NAFLD.84 Skeletal muscle secretes
myokines, such as irisin, that can affect other metabolic organs or tis-
sues.86 Irisin level was inversely associated with the degree of fat accu-
mulation in liver in people with obesity.87 Irisin alleviates insulin
resistance by increasing total body energy expenditure.88 Irisin also
involves peroxisome proliferator‐activated receptor (PPAR)‐α signal-
ling,87 which plays a crucial role in fatty acid β‐oxidation in the liver.89
Thus, NAFLD is emerging as a component of cardiometabolic syn-
drome based on hepatic and peripheral insulin resistance.83,90 Taken
together, these findings suggest that fat accumulation in the liver is
a critical determinant of metabolic flux and inflammatory processes,
thereby representing an important therapeutic target in insulin resis-
tance and T2D.3.5 | Alterations in lipid metabolism in
NAFLD/NASH
The liver plays an important role in lipid synthesis, storage, and release
and is an important site for insulin clearance.91 FFAs overflow to the
liver, either from dietary intake or driven by visceral adipose tissue,
and impaired hepatic elimination of FFAs leads to fat accumulation
in the liver and insulin resistance.92,93 Many clinical and experimental
data show that increased levels of FFAs and their metabolites play
key roles in the onset and progression of lipotoxic liver injury, resulting
in NASH.94
Hepatocytes contain lipid droplets in the lumen of the ER where
VLDL particles are assembled.95,96 Kinetically, FFAs impair insulin‐
induced VLDL1 suppression and this impairment enhances the secre-
tion of triglyceride‐rich VLDL1 particles in individuals with NAFLD or
insulin resistance.97 This increased VLDL1 formation reduces the
amounts of VLDL precursors and decreases the degradation of
apolipoprotein‐B (apoB).98 FFAs also increase basal hepatic glucose
production and induce hepatic insulin resistance through increasing
glucose‐6‐phosphatase activity.99 In addition, an increased FFA level
in hepatocytes reduces the post‐translational degradation of apoB.
FFAs also appear to induce JNK activation, which leads to insulin resis-
tance via IRS‐1 and IRS‐2 serine phosphorylation.100 In another context,
sterol regulatory element‐binding protein‐2 (SREBP‐2), an important
transcription factor in lipid homeostasis, is linked to autophagic func-
tion,101 which is impaired in lipid‐overloaded human hepatocytes or in
those with NAFLD.102 Thus, increased FFAs and subsequent VLDL1
formation are key pathological mechanisms in altering lipid metabolism
found in subjects with NAFLD or insulin resistance.103
A recent study showed that people with NAFLD have lower met-
abolic adaptability throughout metabolic functions related to gluco-
neogenesis and ureagenesis compared with those with lower liver
fat.104 Thus, aberrant lipid metabolism and dysfunctional adipocytes
in the liver recruit multiple cell populations, including macrophages
and other immune cells,105 which contribute to the development of
CVDs.
LIM ET AL. 6053.6 | Oxidative stress is another critical factor in
NAFLD and cardiometabolic syndrome
Many clinical studies have found that markers of oxidative stress, such
as thiobarbituric acid reactive substances, carboxymethyl lysine, and
8‐hydroxy‐deoxyguanosine, are increased in systemic circulation and
liver in patients with NAFLD.106,107 Other markers of oxidative stress
including serum sNOX2‐dp, a NADPH oxidase isoform involved in
generation of oxidative stress108 and urine 8‐iso‐prostaglandin F2α,
from the nonenzymatic oxidation of arachidonic acid,109 are increased
in patients with NAFLD. There is also evidence in support of the acti-
vation of oxidative stress110 and increased levels of homocysteine in
NAFLD.111 In addition to insulin resistance and inflammation, elevated
ALT and γ‐GT activity may result from increased oxidative stress
caused by increased delivery of FFAs to the liver.112,113
Oxidative stress induces endothelial dysfunction,114 which is
likely to predispose people with NAFLD to develop CV events. Thus,
NAFLD may amplify oxidative stress and systemic inflammation, thus
turning on the switch for the initiation of T2D and CVD.3.7 | Other factors related to NAFLD and CVDs
Patients with NAFLD exhibit low levels of adiponectin, which are
associated with insulin resistance, endothelial dysfunction, atheroscle-
rosis, and CV events.115 An in vitro study showed that full‐length
adiponectin treatment suppressed palmitate‐induced fetuin‐A via the
AMPK pathway and improved steatosis.116 In an animal model of dia-
betes, treatment with recombinant adiponectin alleviated hepatic fat
accumulation.117 Further studies are needed to determine whether
the modulation of adiponectin is beneficial in the management of
NAFLD and cardiometabolic syndrome.
ER stress is also associated with the development of
NAFLD/NASH.118 ER stress is defined as a condition in which the
protein‐processing capacity of the ER is exceeded by nascent proteins,
resulting in the accumulation of unfolded or misfolded proteins.119
Accumulating evidence supports a causative role for ER stress in the
development or progression of atherosclerosis.120 Elevated levels of
diagnostic markers of ER stress and increased glycogen synthase
kinase‐3β (GSK‐3β) activity were also found in the livers and athero-
sclerotic lesions in various animal models.118 These data support a role
for ER stress‐induced GSK‐3β activity in the accelerated development
of hepatic steatosis and atherosclerosis. ER stress can also activate
caspases and promote the apoptosis of vascular endothelial cells.121
Factors that are related to fibrinolysis and haemostasis (eg, fibrin-
ogen, tissue plasminogen activator, and plasminogen activator
inhibitor‐1 [PAI‐1]) are strongly associated with NAFLD.122 Interest-
ingly, plasma PAI‐1 levels are more closely associated with fat accu-
mulation in the liver than in adipose tissue, suggesting that fat
deposition in the liver is an important source of PAI‐1 production.123
Taken together, ectopic fat accumulation in the liver and the sub-
sequent alteration of metabolic pathways including inflammation, lipid
metabolism, glucose homeostasis, and oxidation, cause biological dys-
function in vital organs and tissues related to cardiometabolic
syndrome.105,1244 | GENETIC ASSOCIATION BETWEEN
NAFLD/NASH AND CARDIOMETABOLIC
SYNDROME
NAFLD has a complex disease trait with interactions between the
environment and susceptible genes.125,126 NAFLD/NASH and cardio-
metabolic syndrome share several common genes. Genetic polymor-
phisms in the gene for patatin‐like phospholipase domain‐containing
protein 3 (PNPLA3) are associated with the development of fatty liver
and with disease severity.127,128 PNPLA3 encodes the protein
adiponutrin, a triacylglycerol lipase that involves triacylglycerol hydro-
lysis.129 The gene for transmembrane 6 superfamily 2 (TM6SF2), which
regulates plasma lipid levels and hepatic fat contents, is also associ-
ated with NAFLD susceptibility.130 Moreover, TM6SF2 polymorphism
affects glucose homeostasis including pancreatic β‐cell function.131
Furthermore, polymorphisms of PNPLA3 and TM6SF2 suggest a link
with CVDs.132 The gene for membrane‐bound O‐acyltransferase
domain‐containing 7 (MBOAT7), which regulates hepatic fat contents,
is also linked to the development and severity of NAFLD and meta-
bolic derangement.133
Microsomal triglyceride transfer protein (MTP), a lipid transfer
protein, is an essential molecule for the transportation of triglycerides
from the liver to apoB.134 Polymorphisms (−493 G/T) in MTP are
related to the phenotype of NAFLD and insulin resistance.135,136 Sev-
eral studies have shown significant associations between apolipopro-
tein‐C3 (APO‐C3) gene variants and the hepatic fat
accumulation.137,138 APO‐C3 is an apolipoprotein that inhibits lipopro-
tein lipase (LPL) and plays a crucial role in lipid metabolism.139 An
APO‐C3 gain‐of‐function variant associates with the risks of athero-
sclerotic diseases including ischaemic stroke and coronary heart dis-
ease.140,141 However, other studies failed to show any significant
association between variants in APO‐C3 and NAFLD.142,143
In a study with 702 patients with biopsy‐proven NAFLD, the pres-
ence of the ectoenzyme nucleotide pyrophosphate phosphodiesterase
1 (ENPP1)121Gln and IRS‐1 972Arg polymorphisms was indepen-
dently associated with hepatic fibrosis in patients with obesity.144
Polymorphisms in the genes for both proteins are associated with a
marked reduction in AKT activation, reflecting insulin resistance and
disease severity. A recent study found that hepatic lipid synthesis
from polyunsaturated fatty acids is impaired and intrahepatic triglycer-
ide accumulation increased in the transmembrane 6 superfamily
member‐2 E167K gene variant.145 Thus, several genes are proposed
as candidates for NAFLD, but the effects of these genetic abnormali-
ties on NAFLD appear to differ between study groups and remain
controversial.146,147
Of note, there is no evidence of any association between these
genetic variations for NAFLD and CVD.148 In a cohort study of the
Danish general population utilizing Mendelian randomization, a vari-
ant in the gene encoding the PNPLA3, I148M (rs738409) was asso-
ciated with NAFLD (OR 2.03; 95% CI, 1.52‐2.70; P = 3 × 10−7),
but not associated with ischaemic heart disease (OR 0.95; 95% CI,
0.86‐1.04; P = 0.46).148 Therefore, more comprehensive studies
aimed at finding genes that are associated with pathogenesis in
the development of NAFLD related with cardiometabolic syndrome
are warranted.
606 LIM ET AL.5 | CONTRIBUTION OF GUT MICROBIOTA
IN CROSSTALK BETWEEN NAFLD AND
CARDIOMETABOLIC SYNDROME
The liver is closely related to the gut both anatomically and function-
ally; thus, environmental changes in the gut influence the liver via por-
tal circulation. Recent evidence has linked gut dysbiosis, or
compositional shift, to the pathogenesis of NAFLD and cardiometa-
bolic disorders.149,150 People with obesity have a higher pathological
bacterial overgrowth in the small intestine, which contributes to the
development of NAFLD.151 More specifically, microbiota samples
from patients with NAFLD or NASH have a lower proportion of the
family Ruminococcaceae than those from healthy counterparts.152
Patients with NASH have a significantly higher percentage of Clostrid-
ium coccoides, but lower Bacteriodes, than healthy controls or patients
with a simple fat depot in the liver.153
In a whole‐genome shotgun sequencing of fecal samples obtained
from Finnish participants (17.5 million paired‐end reads), Streptococ-
cus, Lactococcus, and Eggerthella counts were increased after low car-
bohydrate and high protein diet, whereas the carbohydrate‐
degrading bacteria Ruminoccocus, Eubacterium, Clostridium, and
Bifidobacterium were decreased, suggesting that dietary intervention
rapidly alters the gut microbiota.48 Furthermore, compositional differ-
ences in gut microbiota were observed according to the degree of
intrahepatic triglyceride content, both in human and animal
studies.154,155
Several mechanistic pathways link NAFLD, metabolic disturbance,
and microbiota. First, short‐chain fatty acids (SCFAs), the major prod-
ucts of carbohydrate fermentation by the gut microbiome, haveFIGURE 3 Roles of gut microbiota in NAFLD and cardiometabolic syndr
and subsequent TLR4‐ or TLR9‐mediated proinflammatory cytokines, ther
changes of gut microbiota produce ethanol and ROS, and then contribute
products into the liver. Enhanced cleavage of choline resulting in the levels
and inflammation. Decreased fasting‐induced adipocyte factor (FIAF) level
transactivation, and lead to increased hepatic fat accumulation. SCFAs pro
gluconeogenesis, and increased energy delivery in the form of SCFAs or c
accumulation and inflammation by gut dysbiosis promote obesity and insuli
[Colour figure can be viewed at wileyonlinelibrary.com]diverse roles in energy metabolism and are major precursors in hepatic
lipogenesis and gluconeogenesis.156 SCFAs shorten bowel transit
time, increase nutrition absorption rates, and transfer of energy
sources to the liver and thereby regulate hepatic lipogenesis and glu-
coneogenesis.157 The types and amounts of SCFAs synthesized in
the gut are influenced by gut dysbiosis and are expected to affect
obesity‐related disorders and NAFLD.158 Second, fasting‐induced adi-
pocyte factor (FIAF) is a protein that is produced in intestinal L‐cells
and inhibits LPL activity. Gut dysbiosis inhibits this intestinal FIAF
secretion and leads to LPL activation, thus promoting fat storage in
adipocytes and the liver.159 Inhibiting FIAF also promotes hepatic pro-
duction of carbohydrate‐responsive element‐binding protein
(ChREBP) and SREBP‐1 and further stimulates fat accumulation in
the liver.159 Third, choline, a water‐soluble essential nutrient, plays
crucial roles in lipid metabolism and promotes lipid transport from
the liver.160 A methionine‐choline deficient diet aggravated gut micro-
biota dysbiosis and induced NASH in an animal model.161 Fourth,
dysbiosis of gut microbiota influences TLR4‐ and TLR9‐mediated
low‐grade inflammation in the liver.162 TLR4 mRNA expression and
plasma levels of LPS, a bacterial‐derived ligand of TLR4, were
increased in biopsy specimen of liver in patients with NASH.163 Fifth,
increase in intestinal permeability and alteration in tight junctions
caused by gut dysbiosis are also observed in patients with NAFLD.164
Recent data indicate that an imbalance in intestinal microbiota or
dysbiosis influences not only NAFLD but also CKD.165 Dysbiosis leads
to an increase in lipopolysaccharide (LPS) levels and bile acids produc-
tions, which are linked to chronic inflammation. The intestinal microbi-
ota also generates trimethylamine oxide, which promotes
atherosclerotic vascular disease.166 Dysbiosis reduces the levels ofome. Gut dysbiosis increases the lipopolysaccharide (LPS) production
eby promoting hepatic inflammation and fibrosis. Compositional
to increased intestinal permeability and transport of proinflammatory
of its toxic metabolites, including trimethylamine, cause liver steatosis
s enhance lipoprotein lipase (LPL) activity and ChREBP and SREBP‐1
duced by the gut microbiota are substrates for hepatic lipogenesis and
arbohydrate results in hepatic steatosis. Increased hepatic fat
n resistance, resulting in risks of NAFLD and cardiometabolic syndrome
LIM ET AL. 607SCFAs and this serves to reduce lipogenesis and to increase gluconeo-
genesis, leading to insulin resistance.167
A recent meta‐analysis revealed that treatment with probiotics
significantly decreased common risk factors of NAFLD and cardiomet-
abolic syndrome.168 It is obvious that there is a robust association
between microbiota changes and the development of NAFLD and
possibly cardiometabolic syndrome via sharing common pathways
including systemic low‐grade inflammation.169 Possible pathological
links between NAFLD and cardiometabolic syndrome are displayed in
Figure 3.6 | CONCLUSIONS
NAFLD is a chronic condition that is characterized by fat accumulation
or inflammation in the liver, or both. Individuals with obesity, insulin
resistance and dyslipidaemia are at the greatest risk of developing
NAFLD. NAFLD is considered a phenotype of cardiometabolic syn-
drome. NAFLD/NASH plays a crucial role in the pathogenesis of
T2D and CVDs via the systemic release of several inflammatory,
prothrombotic, and oxidative stress mediators. NAFLD is linked with
insulin resistance and contributes to atherogenic dyslipidaemia
directly (Figure 2).
Currently, four agents—obeticholic acid, elafibranor, apoptosis sig-
nalling kinase‐1 inhibitor, and cenicriviroc—are being evaluated in
phase 3 trials for the treatment of NASH or NAFLD.170 Before these
medications are available generally (if approved), maintaining a healthy
lifestyle is a fundamental way to prevent or delay the development of
cardiometabolic disease and possibly reverse it in people with existing
NAFLD. Future studies focusing on the molecular mechanism and sig-
nal transduction of the common denominators of NAFLD and cardio-
metabolic syndrome may allow the development of new therapeutic
agents for NAFLD and cardiometabolic disorders.
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